Table VI.
Author/year | Study design | Study groups and sample number | Tissue sampled | Method of analysis | Outcome measure | Direction of effect of in RM/RIF patients |
---|---|---|---|---|---|---|
Lédée et al. (2004) | Prospective case control |
|
Endometrial tissue at luteal phase, either on Day 20 under oestrogen–progesterone replacement or Day 6 post-urinary LH surge | IHC; USS | No clear correlation between cytokine staining/depletion of IL-12 and IL-18, number of NK cells and ultrasound Doppler in RIF or controls | Qualitative analysis |
| ||||||
Lédée-Bataille et al. (2005) | Prospective case control |
|
Endometrial tissue at luteal phase, either on Day 21 under oestrogen–progesterone replacement | IHC; USS; qRT-PCR | • Mean UA PI | ↑ |
• Mean number of NK cells | ↑ | |||||
• Mean ET | ↓ | |||||
• Endometrial (IL-12; IL-15; IL-18) cytokine mRNA ratio | ↔ | |||||
| ||||||
Lédée et al. (2008) | Prospective case control |
|
Endometrial tissue D7-9 post-LH surge | IHC, rtPCR, USS | • Sub-endometrial flow | |
• Uterine artery pulsatility | ||||||
Correlation of cytokine mRNA ratio: | ||||||
with sub-endometrial flow and CD56+ count | ||||||
• IL-15 | POSITIVE* | |||||
With mean UA PI | ||||||
• IL-15 | ||||||
• IL-18 | ||||||
• IL-18BP | NEGATIVE* | |||||
| ||||||
Junovich et al. (2013) | Prospective case control |
|
Endometrial tissue on Day 5–9 after ovulation (by ultrasound) | FC; ELISA | Correlation of CD16+ uNK with endometrial cell culture supernatant protein expression: | |
• IL-6 (n = 28) | NEGATIVE* | |||||
• VEGF (n = 31) | RIF and controls | |||||
| ||||||
Almasry et al. (2015) | Prospective case control |
|
Decidual samples at time of miscarriage/TOP between 6 and 10 weeks gestation | IHC; TEM | Non-remodelling score | POSITIVE* |
RM and controls | ||||||
| ||||||
El-Azzamy et al. (2018) | Prospective case control |
|
Endometrial tissue taken on in mid-luteal phase Day 7–9 post-ovulation | IHC; western blot; qRT-PCR | Correlation of CD56+ cell count with: | |
• VSMC expressing SMM | ↔* | |||||
• CD31+ endothelial cells | ↔* | |||||
| ||||||
Chen et al. (2018) | Prospective case control |
|
Endometrial samples on Day 7 post-LH surge. | Angiogenic array; ELISA | Expression of: | |
• angiogenin | ↑ | |||||
• bFGF | ||||||
• VEGF-A |
Effect direction in relation to RM/RIF group: ↑increase;↓decrease; ↔no difference between the groups.
P < 0.05.
bFGF, basic fibroblast growth factor; ET, endometridal thickness; IHC, immunohistochemistry; IL-18BP, Interleukin-18 binding protein; qRT-PCR, real-time quantitative PCR; RIF, current implantation failure; RM, recurrent miscarriage; SMM, smooth muscle myosin; TEM, transmission electron microscopy; TOP, termination of pregnancy; UA PI, uterine artery pulsatility index; USS, ultrasound scan; VSMC, vascular smooth muscle cells.